Is HQY a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for HealthEquity (HQY) rests on The cash repricing ladder: HealthEquity locks member cash into multi-year contracts with insurance companies and banks, so its yield moves in slow motion rather than with the Fed. The bear case rests on custodial revenue is the profit engine and it depends on rates HealthEquity does not control, so a sustained decline in market yields would eventually reset renewing contracts lower, just as slowly as the current tailwind arrived. Analysts covering it publish targets from $108.00 to $142.00 against a $104.58 share price on November 16, 2026, so even the professionals disagree by 28% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
HQY key stats
At $104.58 on November 16, 2026, HealthEquity (HQY) has a market cap of $8.7B and a P/E of 37.8 on trailing earnings (19.0 on forward earnings). It next reports earnings on December 1, 2026.
- Market cap
- $8.7B
- P/E (trailing)
- 37.8
- P/E (forward)
- 19.0
- EPS (trailing 12 months)
- $2.77
- Price to book
- 4.4
- Beta
- 0.19
- Next earnings
- December 1, 2026
Market cap, P/E and yield are measured at the $104.58 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with HealthEquity (HQY)?
The last two weeks for HealthEquity, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- HQY closed at $104.58 on November 16, 2026, up 2.4% over the past five trading days (from $102.11).
- HealthEquity next reports quarterly results on December 1, 2026.
HealthEquity filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
HealthEquity, Inc. is the largest independent non-bank custodian of health savings accounts in the United States, and it also administers the flexible spending accounts, health reimbursement arrangements, COBRA and commuter benefits that sit alongside them. As of April 30, 2026 it held 10.6 million HSAs containing $37.1 billion of member assets, plus 7.2 million other consumer-directed benefit accounts, for 17.8 million total accounts. Almost none of that comes from consumers directly: it reaches members through their employers, and employers through benefits brokers, health plans and retirement recordkeepers. Revenue arrives in three lines: service fees from employers and members, custodial revenue on the interest spread from member cash placed with insurance-company partners and banks, and interchange on every swipe of a member's benefits card. Custodial is the biggest and by far the most profitable, at $174.3 million of the $354.6 million booked in the quarter ended April 30, 2026, against only $11.7 million of direct cost. The investment question is really about interest rates and where member money sits. Account growth is steady rather than exciting (HSAs up 8% year over year, total accounts up 4%, other benefit accounts flat), so earnings power comes from balances compounding and from old low-rate cash contracts rolling into better ones. HealthEquity disclosed that $16.5 billion of contracted HSA cash earned an average annualized 3.6% at the end of April 2026, with $3.2 billion of it still at 1.8% and due to reprice before the fiscal year ends. Members are also moving cash into markets: invested HSA balances reached $19.6 billion, up 38%, while HSA cash grew just 3%. In May, management raised fiscal 2027 guidance to roughly $1.41 billion to $1.42 billion of revenue and $625 million to $633 million of adjusted EBITDA. The second quarter of fiscal 2027 (ended July 31, 2026, reported August 27) brought revenue of about $350.7 million, up 7.6% year over year, net income of about $65.6 million and adjusted EPS of $1.24, ahead of the $1.19 consensus. Management nudged revenue guidance up only slightly, to $1.411 billion to $1.421 billion, and reiterated adjusted EPS guidance of $4.66 to $4.73; the shares fell 8.6% that week on the modest outlook. In October the company terminated its chief commercial officer, Michael Fiore. About $7.7 billion of market value against $1.36 billion of trailing revenue still leaves little slack if the repricing tailwind fades or if service revenue, up only 3% in the April quarter, keeps decelerating.
The bull case: what would have to be true for $142.00
The most optimistic published target on HQY is $142.00, +35.8% from the $104.58 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. The cash repricing ladder
HealthEquity locks member cash into multi-year contracts with insurance companies and banks, so its yield moves in slow motion rather than with the Fed. At April 30, 2026, $16.5 billion of contracted HSA cash carried an average annualized yield of 3.6%, and the $3.2 billion repricing in the rest of fiscal 2027 was still earning only 1.8%. Custodial revenue rose 11% to $174.3 million in the April 2026 quarter on that mechanic alone, with barely any cost attached.
2. Balances that compound whether or not accounts do
Invested HSA balances hit $19.6 billion, up 38% year over year, and 909,000 accounts now hold investments versus 770,000 a year earlier. HealthEquity charges on invested assets through its service line, so market appreciation and the drift from cash into funds both feed revenue. But money leaving cash for funds also shrinks the custodial base, which is the higher-margin pool.
3. Cost discipline and shrinking the share count
Service costs fell 11% year over year to $78.3 million even as accounts grew, which is where most of the operating leverage in the quarter came from. Gross margin reached 72% that quarter and net income rose 29% to $69.4 million. The company also retired 1.5 million shares for roughly $123.0 million during the quarter, leaving about 83.8 million outstanding. Over the trailing twelve months to July 2026, gross margin was about 71%, operating margin about 28% and net income about $236 million.
4. Policy and the structural HSA tailwind
High-deductible plan enrollment is what creates new HSAs, and Washington has repeatedly widened eligibility rather than narrowed it. HealthEquity opened about 172,000 new accounts from sales in the April 2026 quarter, up 15% from a year earlier. Any legislative expansion of who may fund an HSA lands directly in the account funnel, and any contraction works the same way in reverse.
The bear case: what would have to be true for $108.00
The most pessimistic published target is $108.00, +3.3% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks HealthEquity is worth if the risks below bite instead of the drivers above.
Custodial revenue is the profit engine and it depends on rates HealthEquity does not control, so a sustained decline in market yields would eventually reset renewing contracts lower, just as slowly as the current tailwind arrived. Service revenue grew only 3% in the April 2026 quarter and average service fees per account are falling, which means growth in accounts is not translating cleanly into growth in fees. Competition for the employer default slot is intense, with Optum Bank, Fidelity and HSA Bank all able to undercut on price, and Fidelity in particular markets a no-fee individual HSA. A fiscal 2025 cybersecurity incident involving a business partner's compromised user account left the company facing a consolidated putative consumer class action in federal court in the District of Utah, where it filed a renewed motion to compel arbitration on May 15, 2026, plus several regulatory inquiries; separately, several plaintiff firms have publicized securities investigations following the March 2025 guidance reaction, though the latest 10-Q discloses no pending securities fraud case. Complementary benefit accounts (FSA, HRA, COBRA, commuter) were flat at 7.2 million, so the non-HSA half of the account base is not currently contributing growth. Leadership turnover is a newer watch point: the company terminated Chief Commercial Officer Michael Fiore in October 2026, a role tied directly to winning employer and partner accounts.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding HQY already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on HQY
15 analysts cover HQY, with an average target of $120.67 (+15.4% against $104.58) and a split of 15 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the HQY forecast and price target page.
How is HQY valued?
Market cap, P/E and dividend yield at today's price are in the HQY key stats above. The business figures below come from HealthEquity's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$1.36B
- Latest quarter (Q2 FY2027, ended July 31, 2026): ~$350.7M revenue, +7.6% year over year
- Q2 FY2027 earnings: ~$65.6M net income, ~$1.24 adjusted EPS (vs ~$1.19 expected)
- Margins (TTM): ~71% gross, ~28% operating
- Fiscal 2027 guidance: ~$1.411B to ~$1.421B revenue, ~$4.66 to ~$4.73 adjusted EPS
As of October 2026: HealthEquity runs a January fiscal year, so the quarter ended July 31, 2026 is fiscal 2027's second. At about $92 on October 16, 2026 the stock traded near 34x trailing GAAP earnings and about 17x forward estimates, with EV/EBITDA near 16x; debt of about $971 million against $256 million of cash keeps leverage modest. Because custodial revenue carries almost no direct cost, small changes in the yield on member cash swing earnings far more than equivalent changes in account count.
How do you decide if HQY is a buy?
Whether HQY is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold HQY indirectly through an index or sector ETF before adding more.
What would change your mind on HQY
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: The cash repricing ladder stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: custodial revenue is the profit engine and it depends on rates HealthEquity does not control, so a sustained decline in market yields would eventually reset renewing contracts lower, just as slowly as the current tailwind arrived fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the HQY stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about HQY against your real portfolio and see your actual exposure before deciding.
Your questions about HealthEquity
Ask Walnut's AI anything about HQY and see how it fits what you own.
FAQ
Is HQY a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on The cash repricing ladder, with revenue (ttm) at ~$1.36B. The bear case rests on custodial revenue is the profit engine and it depends on rates HealthEquity does not control, so a sustained decline in market yields would eventually reset renewing contracts lower, just as slowly as the current tailwind arrived. Analysts covering it are spread from $108.00 to $142.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell HQY?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Custodial revenue is the profit engine and it depends on rates HealthEquity does not control, so a sustained decline in market yields would eventually reset renewing contracts lower, just as slowly as the current tailwind arrived. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $108.00, +3.3% from the $104.58 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for HQY?
+
The cash repricing ladder. HealthEquity locks member cash into multi-year contracts with insurance companies and banks, so its yield moves in slow motion rather than with the Fed. The most optimistic analyst target on HQY is $142.00, +35.8% from the $104.58 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for HQY?
+
Custodial revenue is the profit engine and it depends on rates HealthEquity does not control, so a sustained decline in market yields would eventually reset renewing contracts lower, just as slowly as the current tailwind arrived. Service revenue grew only 3% in the April 2026 quarter and average service fees per account are falling, which means growth in accounts is not translating cleanly into growth in fees. Competition for the employer default slot is intense, with Optum Bank, Fidelity and HSA Bank all able to undercut on price, and Fidelity in particular markets a no-fee individual HSA. A fiscal 2025 cybersecurity incident involving a business partner's compromised user account left the company facing a consolidated putative consumer class action in federal court in the District of Utah, where it filed a renewed motion to compel arbitration on May 15, 2026, plus several regulatory inquiries; separately, several plaintiff firms have publicized securities investigations following the March 2025 guidance reaction, though the latest 10-Q discloses no pending securities fraud case. Complementary benefit accounts (FSA, HRA, COBRA, commuter) were flat at 7.2 million, so the non-HSA half of the account base is not currently contributing growth. Leadership turnover is a newer watch point: the company terminated Chief Commercial Officer Michael Fiore in October 2026, a role tied directly to winning employer and partner accounts. The most pessimistic published target is $108.00, +3.3% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does HealthEquity do?
+
HealthEquity is the largest independent non-bank custodian of health savings accounts in the United States, and also administers consumer-directed benefits for employers.
What would have to change for HQY to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The cash repricing ladder) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (custodial revenue is the profit engine and it depends on rates HealthEquity does not control, so a sustained decline in market yields would eventually reset renewing contracts lower, just as slowly as the current tailwind arrived) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does HealthEquity actually do?
+
It is the custodian and administrator behind health savings accounts and related workplace benefit accounts. HealthEquity holds the money, runs the account and the payment card, handles claims substantiation for FSAs and HRAs, and administers COBRA and commuter benefits. As of April 30, 2026 it looked after 10.6 million HSAs and 7.2 million other accounts, 17.8 million in total, for employers across the United States.
How does HealthEquity make money?
+
Three ways. Service revenue is per-account administration fees paid by employers, health plans and members, plus fees on invested balances and its marketplace. Custodial revenue is the spread it keeps on member cash placed with insurance-company partners and banks. Interchange revenue comes from merchants each time a member swipes a benefits card. In the April 2026 quarter those lines were $122.9 million, $174.3 million and $57.4 million.
What is the full legal name of the company that trades as HQY?
+
HealthEquity, Inc., a Delaware corporation headquartered at 15 West Scenic Pointe Drive in Draper, Utah. Its shares trade on the Nasdaq Global Select Market under the ticker HQY, and it files with the SEC under CIK 1428336 and commission file number 001-36568. Its fiscal year ends on January 31, so fiscal 2027 covers February 2026 through January 2027.
Walnut is informational, not investment advice, and gives no verdict on HQY. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.